Rankings
▼
Calendar
AMRX Q1 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q1 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$558M
+12.0% YoY
Gross Profit
$178M
32.0% margin
Operating Income
$34M
6.2% margin
Net Income
-$7M
-1.2% margin
EPS (Diluted)
$-0.07
QoQ Revenue Growth
-8.6%
Cash Flow
Operating Cash Flow
$140M
Free Cash Flow
$128M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$3.6B
Total Liabilities
$3.5B
Stockholders' Equity
$294M
Cash & Equivalents
$145M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$558M
$498M
+12.0%
Gross Profit
$178M
$175M
+2.1%
Operating Income
$34M
$23M
+47.8%
Net Income
-$7M
-$2M
-222.0%
Revenue Segments
Generics Segment
$344M
62%
Av K A R E Segment
$122M
22%
Amneal Specialty Pharma Segment
$92M
16%
← FY 2023
All Quarters
Q2 2023 →